



Protein Kinase C Signalling in Health and Disease: A Commemorative Issue in Honor of Prof. Yasutomi Nishizuka

Guest Editors:

Dr. Aleksandra Romaniuk-Drapała

Department of Clinical Chemistry
and Molecular Diagnostics,
Poznan University of Medical
Sciences, Collegium
Pharmaceuticum, 3 Rokietnicka
Str., 60-806 Poznan, Poland

Dr. Ewa Totoń

Department of Clinical Chemistry
and Molecular Diagnostics,
Poznan University of Medical
Sciences, Collegium
Pharmaceuticum, 3 Rokietnicka
Str., 60-806 Poznan, Poland

Message from the Guest Editors

Dear Colleagues,

This Commemorative Special Issue seeks to honor the great researcher Dr. Yasutomi Nishizuka and his contribution to understanding the dynamic aspects of normal and pathological cell control. We solicit contributions in the form of original research articles and reviews describing the role of protein kinase C (PKC) isozymes in cellular processes such as apoptosis, autophagy, migration, and proliferation, as well as their involvement in various diseases, including metabolic disorders, cancer, and neurodegeneration.

Dr. Aleksandra Romaniuk-Drapała

Dr. Ewa Totoń

Guest Editors

Deadline for manuscript
submissions:

30 June 2024





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)